Myriad Genetics adds folate receptor Alpha to Precise Oncology Solutions Portfolio to expand treatment options for women living with ovarian cancer

June 2, 2023
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE.

Myriad Genetics, Inc. announced the addition of Folate Receptor Alpha (FRα) to its Precise Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.

FRα is a biomarker commonly expressed in patients with ovarian cancer. FRα establishes patient eligibility for ELAHERE (“mirvetuximab soravtansine-gynx”). FRα is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer. According to the SORAYA study, 36% of patients screened were found to have high tumor FRα expression, representing a significant proportion of patients with ovarian cancer who could potentially benefit from MIRV-based therapy.

Myriad Genetics